147 related articles for article (PubMed ID: 17241182)
1. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.
de Vries F; Pouwels S; Lammers JW; Leufkens HG; Bracke M; Cooper C; van Staa TP
J Intern Med; 2007 Feb; 261(2):170-7. PubMed ID: 17241182
[TBL] [Abstract][Full Text] [Related]
2. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study.
de Vries F; Pouwels S; Bracke M; Leufkens HG; Cooper C; Lammers JW; van Staa TP
Pharmacoepidemiol Drug Saf; 2007 Jun; 16(6):612-9. PubMed ID: 16998945
[TBL] [Abstract][Full Text] [Related]
3. Use of anti-depressants and the risk of fracture of the hip or femur.
van den Brand MW; Pouwels S; Samson MM; van Staa TP; Thio B; Cooper C; Leufkens HG; Egberts AC; Verhaar HJ; de Vries F
Osteoporos Int; 2009 Oct; 20(10):1705-13. PubMed ID: 19238308
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study.
Arbouw ME; Movig KL; van Staa TP; Egberts AC; Souverein PC; de Vries F
Osteoporos Int; 2011 Jul; 22(7):2197-204. PubMed ID: 20967420
[TBL] [Abstract][Full Text] [Related]
5. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
[TBL] [Abstract][Full Text] [Related]
6. The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study.
Shen SP; Liu Y; Qiu H; Tsai KY; Wu HC; Liang WM; Shu M; Chou FH
PLoS One; 2019; 14(9):e0221948. PubMed ID: 31487309
[TBL] [Abstract][Full Text] [Related]
7. Fracture risk with intermittent high-dose oral glucocorticoid therapy.
De Vries F; Bracke M; Leufkens HG; Lammers JW; Cooper C; Van Staa TP
Arthritis Rheum; 2007 Jan; 56(1):208-14. PubMed ID: 17195223
[TBL] [Abstract][Full Text] [Related]
8. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.
de Vries F; Souverein PC; Cooper C; Leufkens HG; van Staa TP
Calcif Tissue Int; 2007 Feb; 80(2):69-75. PubMed ID: 17308987
[TBL] [Abstract][Full Text] [Related]
9. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study.
Pouwels S; van Staa TP; Egberts AC; Leufkens HG; Cooper C; de Vries F
Osteoporos Int; 2009 Sep; 20(9):1499-506. PubMed ID: 19156348
[TBL] [Abstract][Full Text] [Related]
11. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study.
Amiche MA; Abtahi S; Driessen JHM; Vestergaard P; de Vries F; Cadarette SM; Burden AM
Arch Osteoporos; 2018 Mar; 13(1):30. PubMed ID: 29552730
[TBL] [Abstract][Full Text] [Related]
12. Use of high-dose intermittent systemic glucocorticoids and the risk of fracture in patients with chronic obstructive pulmonary disease.
Oshagbemi OA; Burden AM; Shudofsky KN; Driessen JHM; Vestergaard P; Krings A; Franssen FME; van den Bergh J; de Vries F
Bone; 2018 May; 110():238-243. PubMed ID: 29462672
[TBL] [Abstract][Full Text] [Related]
13. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
[TBL] [Abstract][Full Text] [Related]
14. Use of alpha-blockers and the risk of hip/femur fractures.
Souverein PC; Van Staa TP; Egberts AC; De la Rosette JJ; Cooper C; Leufkens HG
J Intern Med; 2003 Dec; 254(6):548-54. PubMed ID: 14641795
[TBL] [Abstract][Full Text] [Related]
15. Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis.
Oshagbemi OA; Driessen JHM; Pieffers A; Wouters EFM; Geusens P; Vestergaard P; van den Bergh J; Franssen FME; de Vries F
Osteoporos Int; 2017 Oct; 28(10):2859-2866. PubMed ID: 28638981
[TBL] [Abstract][Full Text] [Related]
16. Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids.
Vestergaard P; Rejnmark L; Mosekilde L
Chest; 2007 Nov; 132(5):1599-607. PubMed ID: 17890464
[TBL] [Abstract][Full Text] [Related]
17. Risk of hip/femur fracture after stroke: a population-based case-control study.
Pouwels S; Lalmohamed A; Leufkens B; de Boer A; Cooper C; van Staa T; de Vries F
Stroke; 2009 Oct; 40(10):3281-5. PubMed ID: 19661475
[TBL] [Abstract][Full Text] [Related]
18. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
[TBL] [Abstract][Full Text] [Related]
19. Fracture risk associated with systemic and topical corticosteroids.
Vestergaard P; Rejnmark L; Mosekilde L
J Intern Med; 2005 Apr; 257(4):374-84. PubMed ID: 15788008
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhaled glucocorticoids and beta(2) agonists on vertebral fracture risk in COPD patients: the EOLO study.
Gonnelli S; Caffarelli C; Maggi S; Guglielmi G; Siviero P; Rossi S; Crepaldi G; Nuti R;
Calcif Tissue Int; 2010 Aug; 87(2):137-43. PubMed ID: 20567964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
